Consultant360 spoke with Zenas Yiu, MBChB, PhD, NIHR Clinical Lecturer in Dermatology at the University of Manchester, about a recent study examining the relationship between psoriasis and risk of serious infection.
Jieyu Ding Featherstone, a PhD student at the University of California Davis, and colleagues conducted a study to better understand the discourse on social media about the flu vaccine during the 2017-2018 flu season. She answered our questions about their study here.
Alexander Egeberg, MD, PhD, discusses his latest research, which suggests that 1 in 4 patients with psoriasis also has psoriatic arthritis.
Scott E. Hadland, MD, MPH, MS: Teens, Young Adults With Opioid Addiction Need Greater Access to Medication
Dr Scott E Hadland from Boston Medical Center discusses his latest research, which demonstrated that prescribing medication earlier to youth with opioid use disorder improves retention in care vs behavioral treatment alone.
In this month's column, Andrea Cedeno, MD, and Kim A. Carmichael, MD, answer questions about continuous glucose monitors, the appropriate patient populations, potential adverse reactions, and more.
Marie Bradley, PhD, MPharm, MScPH, on Apixaban and Warfarin for Stroke Prevention in Patients With NVAF
In this Q&A, Marie Bradley, PhD, discusses a recent study in which researchers examined how the benefit risk of apixaban and warfarin varied by age in patients aged less than 65 years with nonvalvular atrial fibrillation.
In this Q&A, Sara Reece, PharmD, CDCES, discusses the use of GLP-1 agonists and SGLT-2 inhibitors to improve cardiovascular and renal outcomes in patients with type 2 diabetes.
The AAN released guidelines for the treatment of insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder. In this Q&A, Ashura Williams Buckley, MD, lead author of the guidelines and the director of Sleep and Neurodevelopment Service at the NIMH discusses them in further detail.
New research sheds light on a novel biomarker that may accurately predict new-onset peripheral arterial disease in patients with mild to moderate chronic kidney disease. Researcher Scott E. Janus, MD, answers our questions.
While SGLT-2 inhibitors are often used in patients with type 2 diabetes, this class of medication can also be used to treat patients with heart failure. In this Q&A, Jennifer Clements, PharmD, discusses a session she recently presented at ADCES21, on the use of SGLT-2 inhibitors in patients with heart failure.